Enoblituzumab

DB15017InvestigationalProtein Based Therapies

Enoblituzumab is under investigation in clinical trial NCT02982941 (Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors).

Mechanism
Curator reviewed
Code names
MGA271

Resolves to

Compound
UNIIM6030H73N9CAS1353485-38-7
Targets
Q5ZPR3CD276

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
10Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Enoblituzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In